Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Research Grant to Fund Development of Novel Tumor-Imaging Nanoprobes

By BiotechDaily International staff writers
Posted on 04 Nov 2013
Research funds have been awarded that will support a collaborative effort to develop novel nanoprobes to be used for in vivo tumor imaging.

Rockland Immunochemicals Inc. (Gilbertsville, PA, USA) and Abzyme Therapeutics (Malvern, PA, USA) have received a Phase I Small Business Innovation Research (SBIR) grant from the [US] National Cancer Institute (Bethesda, MD, USA) to develop nanoprobes for in vivo imaging of tumors that express the important cancer therapeutic targets: EGFR (epidermal growth factor receptor), Her2 (human epidermal growth factor receptor 2), or mesothelin.

According to the terms of the grant, during the first phase the partners will develop, label, and characterize high-affinity single domain antibodies against the three tumor antigens. Abzyme Therapeutics will develop the single domain antibodies, and Rockland will be responsible for bioconjugation and in vivo characterization.

In the planned second phase of the project, the key antibodies will be labeled with a radioactive isotope and characterized using PET scanners in collaboration with Yale University (New Haven, CT, USA) and the University of Pittsburg (PA, USA). Suitable radioactively labeled antibodies will be used as in vivo imaging agents, and their potential use in targeted cancer therapy will be considered.

“In these times of shrinking government investment in research, this SBIR grant validates Rockland’s business model of collaboration with leading academic institutions to aggregate, develop, and commercialize technologies that will ultimately benefit humanity,” said Jim Fendrick, president and CEO of Rockland Immunochemicals. “This research is in line with the company’s expertise in antibodies and antibody based tools. We are confident that this collaboration will generate significant innovation and that the results will have great scientific and commercial applications.”

According to the market research firm Markets and Markets (Pune, India), the global diagnostic imaging market, which stood at USD 20.7 billion in 2010, is expected to expand to USD 26.6 billion by 2016. This expected rise is attributed to an aging population, increasing awareness about preventive care, and advancements in the field.

Related Links:
Rockland Immunochemicals Inc.
Abzyme Therapeutics
[US] National Cancer Institute




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.